ATE538808T1 - Kombinierte dns/protein impfstoffzusammensetzungen - Google Patents

Kombinierte dns/protein impfstoffzusammensetzungen

Info

Publication number: ATE538808T1
Authority: AT; Austria
Prior art keywords: dna; combined dna; vaccine compositions; protein vaccine; combined
Prior art date: 2002-03-28

Application number

AT03720397T

Other languages

English (en)

Inventor

Hansjoerg Reimann

Reinhold Schirmbeck

Erik Lindblad

Original Assignee

Brenntag Biosector As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2003-03-28

Publication date

2012-01-15

2003-03-28 Application filed by Brenntag Biosector As filed Critical Brenntag Biosector As

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538808T1 publication Critical patent/ATE538808T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
229940023143 protein vaccine Drugs 0.000 title abstract 2
108010041986 DNA Vaccines Proteins 0.000 abstract 3
229940021995 DNA vaccine Drugs 0.000 abstract 3
239000002671 adjuvant Substances 0.000 abstract 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
229910052782 aluminium Inorganic materials 0.000 abstract 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000005847 immunogenicity Effects 0.000 abstract 1
229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
239000011707 mineral Substances 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT03720397T 2002-03-28 2003-03-28 Kombinierte dns/protein impfstoffzusammensetzungen ATE538808T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02076276		2002-03-28
EP03075383		2003-02-10
PCT/EP2003/003353 WO2003082327A2 (en)	2002-03-28	2003-03-28	Combined dna/protein vaccine compositions

Publications (1)

Publication Number	Publication Date
ATE538808T1 true ATE538808T1 (de)	2012-01-15

Family

ID=28676388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03720397T ATE538808T1 (de)	2002-03-28	2003-03-28	Kombinierte dns/protein impfstoffzusammensetzungen

Country Status (9)

Country	Link
US (1)	US20050129712A1 (de)
EP (1)	EP1490100B1 (de)
AT (1)	ATE538808T1 (de)
AU (1)	AU2003224017A1 (de)
CA (1)	CA2480690A1 (de)
DK (1)	DK1490100T3 (de)
ES (1)	ES2379346T3 (de)
IL (1)	IL164256A0 (de)
WO (1)	WO2003082327A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2672992T (pt)	2011-02-11	2020-07-27	Univ Pennsylvania	Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma
US9238679B2 (en)	2011-02-11	2016-01-19	The Trustees Of The University Of Pennslyvania	Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CN111388662B (zh) *	2020-03-12	2023-03-10	潍坊华英生物科技有限公司	一种小鹅瘟病毒的复合疫苗及卵黄抗体制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0835663B1 (de) *	1992-05-23	2009-09-30	GlaxoSmithKline Biologicals S.A.	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
CA2244110A1 (en) *	1996-02-12	1997-08-14	Cobra Therapeutics Limited	Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
GB9726555D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Vaccine
CA2336992A1 (en) *	1998-07-09	2000-01-20	Merck & Co., Inc.	Polynucleotide vaccine formulations
GB9910375D0 (en) *	1999-05-05	1999-06-30	Lindahl Gunnar	Vaccine composition

2003
- 2003-03-28 IL IL16425603A patent/IL164256A0/xx unknown
- 2003-03-28 EP EP03720397A patent/EP1490100B1/de not_active Expired - Lifetime
- 2003-03-28 AU AU2003224017A patent/AU2003224017A1/en not_active Abandoned
- 2003-03-28 ES ES03720397T patent/ES2379346T3/es not_active Expired - Lifetime
- 2003-03-28 DK DK03720397.3T patent/DK1490100T3/da active
- 2003-03-28 CA CA002480690A patent/CA2480690A1/en not_active Abandoned
- 2003-03-28 WO PCT/EP2003/003353 patent/WO2003082327A2/en not_active Application Discontinuation
- 2003-03-28 US US10/509,498 patent/US20050129712A1/en not_active Abandoned
- 2003-03-28 AT AT03720397T patent/ATE538808T1/de active

Also Published As

Publication number	Publication date
CA2480690A1 (en)	2003-10-09
AU2003224017A1 (en)	2003-10-13
US20050129712A1 (en)	2005-06-16
IL164256A0 (en)	2005-12-18
EP1490100A2 (de)	2004-12-29
WO2003082327A2 (en)	2003-10-09
ES2379346T3 (es)	2012-04-25
DK1490100T3 (da)	2012-03-12
EP1490100B1 (de)	2011-12-28
WO2003082327A3 (en)	2004-03-04

Publication	Publication Date	Title
ES2875589T3 (es)	2021-11-10	Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm
NL300899I2 (nl)	2018-04-06	Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
IL150602A (en)	2010-12-30	Proteosome influenza vaccine, method for preparing such and use thereof
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
CY1112749T1 (el)	2016-02-10	Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
DE122011100053I1 (de)	2012-03-15	Influenza vakzinzusammensetzungen zur intradermaler verabreichung.
BRPI0607840A2 (pt)	2009-06-13	uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
AU2005332599A8 (en)	2008-03-20	Polyinosinic acid-polycytidylic acid-based adjuvant
RU2009144125A (ru)	2011-07-27	Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
WO2006136460A3 (en)	2007-06-14	New adjuvant
GB2386072A (en)	2003-09-10	Novel vaccine
ATE284613T1 (de)	2005-01-15	Polynukleotid-impfstoff-formulierungen
ATE538808T1 (de)	2012-01-15	Kombinierte dns/protein impfstoffzusammensetzungen
WO2003095480A3 (en)	2004-03-11	Brachyspira hyodysenteriae vaccine
WO2003080112A3 (en)	2003-11-06	Imidazoquinolineamines as adjuvants in hiv dna vaccination
CO5300406A1 (es)	2003-07-31	Vacuna
WO2004007726A3 (en)	2004-02-19	Brachyspira hyodysenteriae vaccine
Buaklin et al.	2014	Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein
DE602005021873D1 (de)	2010-07-29	Neues impfstoffadjuvans und dessen herstellung und verwendung
DK1227840T3 (da)	2008-02-04	Adjuverede, genetiske vacciner
DE69942161D1 (de)	2010-04-29	Genetische Adjuvanz-Impfstoffe
WO2005030802A3 (en)	2005-09-09	Antigens for an east coast fever vaccine